Relmada Therapeutics, Inc. Share Price

Relmada Therapeutics, Inc. Share Price

NASDAQ: RLMD | Micro Cap
$3.90
+$0.14 (3.72%) Last updated on 07 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Relmada Therapeutics, Inc. Stock Performance

Open
$3.80
Prev. Close
$3.77
Circuit Range
N/A
Day Range
$3.69 - $3.97
Year Range
$2.45 - $7.99
Volume
1,01,414
Average Traded
$3.88

Relmada Therapeutics, Inc. Share Price Today

As of 8 November 2026, Relmada Therapeutics, Inc.'s share price is $3.90. The stock opened at $3.80, compared to its previous close of $3.77. During today's trading session, Relmada Therapeutics, Inc.'s share price traded between $3.69 and $3.97, with an average price of $3.83. Over the past 52 weeks, the stock has recorded a high of $7.99 and a low of $2.45. In terms of performance, Relmada Therapeutics, Inc.'s share price has declined by 45.91% over the last six months and is down 13.61% on a year-on-year basis.

Relmada Therapeutics, Inc. Share Price Chart

Line chart of the Relmada Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 3.69 to 3.97, ending at 3.90.
$3.69$3.97
L
Show Current Price
H

Relmada Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$154.17M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.58
Revenue (TTM)
$0.00
Return On Equity (TTM)
-29.98%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-27.95%

Relmada Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$10.09-$19.87-$19.05-$12.91
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-96.93%4.13%32.23%

Relmada Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$157.04-$98.79-$79.98-$57.39
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A37.09%19.04%28.24%

About Relmada Therapeutics, Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Relmada Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.60
$3.92
+9.65%
Oct 2026
$3.74
$3.58
-5.05%
Sep 2026
$4.34
$3.77
-16.70%
Aug 2026
$5.09
$4.52
-14.88%
Jul 2026
$6.83
$5.31
-23.38%
Jun 2026
$7.03
$6.93
-4.02%
May 2026
$7.61
$7.22
-4.18%
Apr 2026
$7.03
$7.54
+8.57%
Mar 2026
$4.71
$6.94
+53.20%
Feb 2026
$3.68
$4.53
+27.61%
Jan 2026
$4.75
$3.55
-26.42%
Dec 2025
$4.44
$4.83
+6.75%

RLMD Share Price FAQs